Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults.

Area of Science:

• Gastroenterology
• Immunology
• Microbiology

Background:

• Helicobacter pylori infection is a global health concern.
• Oral immunization with urease has shown promise in animal models for curing H. pylori infections.
• Therapeutic immunization strategies are being explored for human H. pylori infections.

Purpose of the Study:

• To evaluate the safety and immunogenicity of oral recombinant H. pylori urease in H. pylori-infected adults.
• To assess the impact of oral urease immunization on H. pylori infection density.

Main Methods:

• A double-blind, randomized study involving 26 H. pylori-infected volunteers.
• Participants received weekly oral doses of varying urease concentrations (20, 60, 180 mg) combined with heat-labile enterotoxin (LT) or placebo.
• Safety, immune responses (serum and cellular), and gastric H. pylori levels were monitored.

Main Results:

• Oral urease immunization was generally well-tolerated, with diarrhea reported in 66% of participants.
• Significant increases in antiurease serum immunoglobulin A titers and circulating immunoglobulin A-producing cells were observed.
• No eradication of H. pylori was achieved, but a significant reduction in gastric H. pylori density was noted.

Conclusions:

• Oral immunization with H. pylori urease and LT is safe and immunogenic in infected individuals.
• The formulation induced a measurable immune response and reduced bacterial load.
• Further development of vaccine formulations may be necessary to achieve curative immunity.